SAN CARLOS, Calif., March 25, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, announced that Lynn R. Webster, M.D., FACPM, FASAM, Co-Founder and Medical Director of Lifetree Clinical Research, will introduce the Company's novel technology during the 27th Annual American Academy of Pain Medicine (AAPM) Meeting.
Dr. Webster's presentation, titled "New Opioid Formulations and Delivery Systems," will feature PharmacoFore's Bio-Activated Molecular Delivery™ (also referred to as Bio-MD™) and MPAR™ technologies on Saturday, March 26, 2011, at 3:00 p.m. EDT at the Gaylord National Convention Center in National Harbor, MD.
"PharmacoFore's new opioid drug technology may offer the medical community a truly revolutionary approach to safer opioid prescribing," said Dr. Webster, a world leader in pain management and prescription drug abuse. "The new delivery system may prevent individuals from overdosing with multiple pills while allowing prescribers to determine the dose that is most appropriate for the patient."
According to Dr. Steven Passik, Professor of Psychiatry and Anesthesiology, Vanderbilt University Medical Center, "We have two public health crises – the crisis of pain and the crisis of prescription drug abuse, and we need a balanced approach that doesn't address one at the expense of the other. PharmacoFore's technology has the potential to reduce barriers to effective pain management while offering an unprecedented level of resistance to all common routes of abuse."
PharmacoFore has created a novel Bio-Activated Molecular Delivery technology designed to effectively deter prescription drug abuse at a molecular level. This technology does not involve (1) the reformulation of existing opioid drugs in physical matrices that are easily circumvented by simple extraction methods; or (2) adding aversive agents
|SOURCE PharmacoFore, Inc.|
Copyright©2010 PR Newswire.
All rights reserved